Procept BioRobotics Faces Revenue Shortfall Amid Pricing Changes, Legal Investigation Opens

Procept BioRobotics Faces Challenges Following Earnings Report

Procept BioRobotics, trading under NASDAQ ticker PRCT, has recently made headlines following its guidance for the fiscal year 2025. The company projected impressive revenues of $325.5 million, indicating a substantial growth rate of 45%. However, the reality turned out to be less rosy as their actual revenue resulted in a disappointing $308.1 million, leaving them $17.4 million short of their forecast. This significant revenue gap has sparked a sharp decline in their stock value, dropping by more than 15% in a single day.

This financial shortfall is further compounded by a recent strategic initiative aimed at altering pricing structures for their products. During a Q3 earnings call on November 4, 2025, CFO Kevin Waters reiterated the ambitious revenue target and confirmed that the average selling price for the company’s handpiece would be maintained at around $3,200. In support of this, CEO Larry Wood emphasized that the company's investments in critical areas would not hinder their journey towards profitability.

However, this optimism was tempered by the actual market situation. Procept BioRobotics had introduced a new pricing discipline that curtailed bulk-purchase discounts historically offered to their consumers. This move, intended to stabilize prices, inadvertently lowered the realized average selling prices for their key product line.

Analysts were taken aback when Procept’s fourth-quarter results revealed not just a revenue missing the guidance but also expectations for the next fiscal year were set at $410 million to $430 million, which again fell short of what many analysts had anticipated. This led to further skepticism in the market regarding the company's short and long-term viability.

In response to the revenue shortfall and the fallout from these pricing changes, Levi & Korsinsky, LLP has initiated an investigation concerning the situation. The firm is reaching out to shareholders who experienced losses due to these developments, inviting them to discuss potential legal actions.

For investors impacted by these developments, it's crucial to be informed about your rights. Interested parties are encouraged to connect with Joseph E. Levi, Esq., who is leading this investigation, for guidance on the next steps. Communication can be facilitated through email or by phone, ensuring that affected shareholders have a platform to voice their concerns.

This situation unfolds in a rapidly evolving economic climate, where companies are under increased pressure to deliver on their financial commitments amidst changing market dynamics and consumer behavior. As Procept BioRobotics navigates these challenges, stakeholders will be closely watching to see how the company adjusts its strategies and whether it can regain investor confidence.

As we continue to monitor Procept's path forward, it remains essential for shareholders and potential investors to stay updated on any further disclosures and financial reports, which may shed light on the company’s recovery strategies or shift in market approach. Procept’s ability to adapt to these ongoing challenges may ultimately determine its future success and stability in the highly competitive medical technology landscape.